Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Non-small-cell Lung Cancer (NSCLC)
Interventions
DRUG

Tislelizumab

Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, neoadjuvant therapy : 2-4 cycles; Adjuvant therapy: 16cycles at most.

DRUG

Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)

Pemetrexed: 500 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.

DRUG

Carboplatin or Cisplatin

"Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 of each 21-day cycle for 2-4 cycles.~Cisplatin: 75 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles."

PROCEDURE

Surgery

Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.

Trial Locations (1)

266000

RECRUITING

the Affiliated Hospital of Qingdao University, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER